DarioHealth (NASDAQ:DRIO) Director Dennis Matheis Acquires 14,430 Shares

DarioHealth Corp. (NASDAQ:DRIO) Director Dennis Matheis acquired 14,430 shares of the stock in a transaction dated Thursday, July 23rd. The stock was bought at an average price of $6.93 per share, for a total transaction of $99,999.90. Following the completion of the purchase, the director owned 43,026 shares in the company, valued at approximately $298,170.18. This trade represents a 50.46% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

DarioHealth Trading Up 0.3%

Shares of DRIO opened at $7.49 on Wednesday. The company has a current ratio of 3.07, a quick ratio of 2.62 and a debt-to-equity ratio of 0.50. The stock has a market cap of $54.99 million, a PE ratio of -0.84 and a beta of 1.09. DarioHealth Corp. has a 1 year low of $5.84 and a 1 year high of $17.74. The stock has a 50 day simple moving average of $7.18 and a 200-day simple moving average of $8.64.

Institutional Trading of DarioHealth

Large investors have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new stake in shares of DarioHealth in the fourth quarter valued at $35,000. Geode Capital Management LLC lifted its position in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after buying an additional 31,063 shares in the last quarter. Finally, XTX Topco Ltd grew its holdings in DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares during the last quarter. Institutional investors own 33.39% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of DarioHealth in a research note on Friday, July 10th. TD Cowen reiterated a “hold” rating and set a $11.00 target price on shares of DarioHealth in a research report on Wednesday, May 13th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $10.00 price target on shares of DarioHealth in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.50.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.